A set of reproducible biomarkers are associated with better response rates to anti–PD-1 therapy in patients with advanced melanoma.
A rapid EGFR-specific assay allowed for quicker identification of EGFR mutation–positive NSCLC, and thus a shorter time to initiation of EGFR-directed therapy.
The intratumoral vasculature of high-grade serous ovarian cancer does not appear to undergo significant changes during disease progression.
Treatment of high-risk melanoma with adjuvant bevacizumab following resection improves disease-free survival over standard observation, but not overall survival.
Recent use of aspirin or NSAIDs is associated with improved ovarian cancer–specific survival.
Researchers identified the percentage cutoff for ALK positivity that is needed for clinical utility in ALK-positive NSCLC.
TURBT with fluorescent light source using oral 5-ALA is well tolerated in non–muscle-invasive bladder cancer.
Melanoma patients who were treated with glucocorticoids for ipilimumab-induced hypophysitis had improved survival outcomes if they received low doses.
Patients with muscle-invasive bladder cancer who underwent trimodal therapy had significantly poorer survival than those who underwent radical cystectomy alone.
Germline BRCA mutations and other HR genes may offer biomarkers for response to this treatment.